Want to see IT:EUK full AI Analyst Report?
Eukedos S.p.A. (EUK) AI Stock Analysis
Eukedos S.p.A.
(Milan:EUK)
Primarily impacted by poor financial performance characterized by high leverage and inconsistent profitability, alongside bearish technical indicators and unfavorable valuation due to negative earnings.
Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 10.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 941
- Price to Earnings (P/E)
- 23.9
- Beta (1Y)
- 0.32
- Revenue Growth
- 3.21%
- EPS Growth
- ―
- Country
- Italy
- Employees
- 613
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Eukedos S.p.A. Business Overview & Revenue Model
Company Description
EuKedos S.p.A. operates in Italy, offering a range of managed and long-term care provisions. The company specializes in delivering residential social support for older adults, catering to both independent individuals and those needing extensive assis...
How the Company Makes Money
Eukedos makes money primarily by operating and managing healthcare and social assistance services and facilities. Revenue is generated through fees and reimbursements tied to the delivery of care services (e.g., residential care, assisted living, and...
Eukedos S.p.A. Financial Statement Overview
Summary
Weak income statement with net losses, poor balance sheet due to high debt-to-equity of 4.41, and mixed cash flows lead to a minimal financial score.
Income Statement
35NegativeBalance Sheet
28NegativeCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.95M | 51.64M | 51.69M | 49.45M | 47.04M | 45.18M |
| Gross Profit | 12.71M | 12.09M | 48.96M | 13.73M | 32.03M | 32.99M |
| EBITDA | 11.89M | 10.26M | 12.27M | 12.41M | 10.87M | 10.72M |
| Net Income | 457.00K | -749.00K | -524.00K | 556.00K | 443.00K | 570.00K |
Balance Sheet | ||||||
| Total Assets | 185.21M | 180.33M | 179.34M | 149.10M | 153.38M | 150.08M |
| Cash, Cash Equivalents and Short-Term Investments | 848.00K | 416.00K | 3.91M | 2.33M | 3.62M | 7.39M |
| Total Debt | 128.99M | 128.29M | 99.02M | 105.83M | 111.45M | 108.95M |
| Total Liabilities | 154.68M | 151.23M | 149.50M | 119.19M | 123.99M | 121.26M |
| Stockholders Equity | 30.53M | 29.10M | 29.84M | 29.91M | 29.39M | 28.82M |
Cash Flow | ||||||
| Free Cash Flow | 329.00K | 436.00K | -13.14M | 3.59M | 1.03M | 5.31M |
| Operating Cash Flow | 7.74M | 6.24M | 9.94M | 10.08M | 5.18M | 5.61M |
| Investing Cash Flow | -6.09M | -5.86M | -58.49M | -8.92M | -4.15M | -306.00K |
| Financing Cash Flow | -3.49M | -3.87M | 50.13M | -2.45M | -4.79M | -562.00K |
Eukedos S.p.A. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Negative. The current price of 0.48 is below the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.51, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.16 is Neutral, neither overbought nor oversold. The STOCH value of 5.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:EUK.
Eukedos S.p.A. Peers Comparison
Overall Rating
- IT:EUK39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IT:EUK | 39Underperform | EUR 10.92M | 23.88 | ― | ― | 3.21% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:EUK | Eukedos S.p.A. | 0.48 | -0.28 | -36.42% | |
| IT:ARBS | Arterra Bioscience SpA | 2.99 | 0.06 | 2.08% | |
| IT:COSMO | Farmacosmo S.P.A. | 0.41 | -0.06 | -13.01% | |
| IT:SVS | Svas Biosana S.p.A. | 8.00 | -1.88 | -19.00% | |
| IT:IMD | I.M.D. International Medical Devices S.P.A. | 1.29 | -0.14 | -9.79% | |
| IT:PMED | Piu Medical S.P.A. | 5.25 | -0.55 | -9.56% |
Eukedos S.p.A. Corporate Events
Eukedos Revises Board Line-Up and Committees After Co-Option Change
Eukedos S.p.A. has announced that Lenthona, previously designated by co-option as an independent, non-executive director, has declined the appointment due to concerns over interpretative uncertainties pending new implementing regulations under the up...
Eukedos Names New Officer in Charge of Accounting Documents
Eukedos S.p.A., an Italian healthcare and social care services provider focused on elderly and assisted living facilities, operates under the direction and coordination of La Villa S.p.A. and manages a portfolio of care-focused assets across Italy. T...
Eukedos Reshapes Portfolio and Financing to Back New Elderly Residences
Eukedos S.p.A. has sold its 40.24% stake in Poggio Imperiale Srl to related party La Veranella Srl for €2.6 million, consolidating ownership of the company under an entity that already held the majority. The agreed price, previously disclosed t...
Eukedos Publishes Minutes of 29 April 2026 Shareholders’ Meeting
Eukedos S.p.A. has made available to the public the minutes of its Ordinary Shareholders’ Meeting held on 29 April 2026, in line with regulatory and governance best practices. The documents can be consulted at the company’s registered off...
Eukedos Sells Poggio Imperiale Stake and Refreshes Board Composition
Eukedos has approved the sale of its 40.24% stake in Poggio Imperiale S.r.l. to related party La Veranella S.r.l., a company fully owned by La Villa S.p.A., which already controls Poggio Imperiale. The transaction, priced at 2.6 million euro and yiel...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026